CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma

Maja Šutić1, Jurica Baranašić1, Lana Kovač Bilić2, Mario Bilić2, Antonija Jakovčević2, Luka Brčić4, Sven Seiwerth3, Marko Jakopović5, Miroslav Samaržija5, Ulrich Zechner6 and Jelena Knežević1,7*

Abstract

Background: Patients with head and neck squamous cell carcinoma (HNSCC) can develop lung squamous cell carcinoma (LuSCC), which could be the second primary tumor or HNSCC metastasis. Morphologically it is difficult to distinguish metastatic HNSCC from a second primary tumor which presents a significant diagnostic challenge. Differentiation of those two malignancies is important because the recommended treatments for metastatic HNSCC and primary LuSCC differ significantly. We investigated if the quantification of the promoter methylation status in HNSCC and LuSCC differs.

Methods: Primary HNSCC ($N = 36$) and LuSCC ($N = 17$) were included in this study. Methylation status in the ASC/TMS1/PYCARD (apoptosis-associated speck-like protein containing a caspase recruitment domain; 8 CpG sites) and MyD88 (Myeloid differentiation primary response protein 88; 10 CpG sites) promoters was analyzed. Bisulfite converted DNA, isolated from tumor tissue was quantified using pyrosequencing. Results of pyrosequencing analysis were expressed as a percentage for each tested CpG site. Receiver-operating characteristic (ROC) curve analysis was used for the evaluation of the diagnostic properties of selected biomarkers.

Results: CpG sites located in the promoters of ASC/TMS1/PYCARD_CpG8 (− 65 upstream) and MyD88_CpG4 (− 278 upstream) are significantly hypermethylated in the HNSCC when compared with LuSCC ($p \leq 0.0001$). By performing ROC curve analysis we showed that corresponding areas under the curve (AUC) were $85–95\%$, indicating that selected CpG sites are useful for a distinction between primary LuSCC and primary HNSCC.

(Continued on next page)
Introduction

Patients diagnosed with head and neck squamous cell carcinoma (HNSCC) can present with lung metastases, or develop second primary lung tumors [1]. The occurrence of concurrent lung malignancies, i.e. presence of solitary lung nodules in patients with extrathoracic malignancies, like HNSCC, is frequent and always challenging for both oncologists and pathologists [2]. Even after pathologic assessment, the real nature of a solitary lung nodule in patients with HNSCC often remains ambiguous. The distinction between lung metastasis and a primary lung carcinoma for radiologists can be straightforward if metastatic disease presents with multiple lung nodules of varying sizes. On the other hand, solitary lung nodule could represent lung metastasis or primary lung carcinoma [3]. Given their morphologic similarities, lung metastases and primary squamous cell carcinoma of the lung (LuSCC) cannot be distinguished based on histopathologic characteristics. The differential diagnosis between second primary LuSCC and HNSCC metastasis in the lung is mainly dependent on clinical criteria such as localization of the lung lesion, tumor stage of HNSCC, and disease-free interval. However, some clinical criteria for this distinction, like duration of disease-free period (carcinoma in the lung is regarded as a metastasis when detected within 2–5 years after another primary tumor was diagnosed, and as a new primary when detected beyond this threshold), are empirical and non-accurate [4].

In our previous work, we have shown that the methylation status of two genes, ASC/TMS1/PYCARD (apoptosis-associated speck-like protein containing a caspase recruitment domain) and MyD88 (Myeloid differentiation primary response protein 88), could be considered as a promising biomarker in non-small cell lung cancer (NSCLC) in distinguishing healthy from tumor tissue [5]. We found that both genes are hypomethylated in tumor tissue when compared to adjacent non-tumor tissue. Furthermore, we found that the methylation status of tested genes in tumor tissue could be used as a potential prognostic biomarker in patients with early-stage NSCLC because hypomethylation of specific CpG sites in ASC/TMS1/PYCARD gene was associated with reduced overall survival.

The fact that there is no fast and reliable diagnostic protocol for distinguishing between second primary LuSCC from HNSCC metastasis to the lung, motivated us to use primary tumor tissues (LuSCC and HNSCC) and investigate if they can be distinguished on methylation level of selected genes. We were using a pyrosequencing approach, still considered a gold standard in methylation study [6].

Material and methods

All the protocols and molecular methods used in this study have been described in detail in our previously published data [5].

Study cohort

This study was conducted on freshly frozen primary tumor samples. Early-stage resected squamous cell carcinoma of the lung (LuSCC) (N = 17) and head and neck squamous cell carcinoma (HNSCC) (N = 36) were obtained during surgery (University Hospital Centre Zagreb, Department for Respiratory Diseases Jordanovac, Zagreb, Croatia and Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Centre Zagreb, Croatia). Tissue samples were snap-frozen in liquid nitrogen and stored at −80 °C. Cancer tissues were analyzed by pathologists on hematoxylin and eosin stained slides, and samples with a minimum of 70% of tumor cells were preceded for further analysis. The clinical and pathological features of the patients are shown in Table 1. All patients signed informed consent and the study was approved by the local ethics committee (University Hospital Centre Zagreb).

CpG analysis

DNA, isolated from freshly frozen tumor tissue samples, was bisulfite converted, amplified, and sequenced. For this study, we have analyzed the methylation status of the MyD88 and ASC/TMS1/PYCARD genes in the primary HNSCC and compared them with methylation status in the primary LuSCC samples obtained in the previously mentioned study. We have analyzed 8 different CpG sites in the promoter region of the ASC/TMS1/ PYCARD gene and 10 different CpG sites in the MyD88 gene. Locations of the tested CpG sites in the ASC/TMS1/PYCARD gene are as follows: CpG1 + 52; CpG2 + 49; CpG3 + 33; CpG4 + 134; CpG5 + 129; CpG6 + 76; CpG7 + 71; CpG8 + 65. Locations of the tested CpG sites

Conclusions:

Results of the present study indicate that there is a significant difference in the methylation status of tested genes between primary HNSCC and LuSCC. However, to prove this approach as a useful tool for distinguishing second primary LuSCC from HNSCC metastasis, it would be necessary to include a larger number of samples, and most importantly, metastatic samples.

Keywords: HNSCC, Second primary tumor, Lung, Diagnostic biomarker, Methylation, CpG
in the MyD88 gene are as follows: CpG1–253; CpG2–256; CpG3–267; CpG4–278; CpG5–210; CpG6–216; CpG7–222; CpG8–146; CpG9–151; CpG10–167. Indicated values represent a distance from the transcriptional start site. Schematic locations of the tested CpG sites and tested genes are presented in the Fig. 1a and b. Results of the pyrosequencing analysis were expressed as a percentage for each analyzed CpG site.

Statistical analysis
Differences in methylation status were tested using a paired t-test. To define the possible diagnostic applicability of selected CpG sites, receiver operating characteristic (ROC) curves analysis was performed. To assess the diagnostic properties of selected CpG sites, ROC curves, the areas under curves (AUC) together with 95% confidence intervals (95% CI) were plotted. For this analysis values of methylation status (%) of selected CpG sites (ASC/TMS1/PYCARD_CpG8 and MyD88_CpG4), detected for each sample in HNSCC and LuSCC, were plotted.

Results
Analysis of the methylation status demonstrated that the methylation pattern of ASC/TMS1/PYCARD and MyD88 promoters is different between primary tumors in HNSC C and LuSCC sample cohorts. We have shown that ASC/TMS1/PYCARD_CpG8 (located –65 upstream) is significantly hypermethylated in primary HNSCC (11.47%) in comparison to LuSCC (4.65%) (p < 0.0001) (Fig. 1c). Additionally, we have found that MyD88_CpG4 (located –278 upstream) is significantly hypermethylated in HNSCC (19.96%) when compared to LuSCC (10.2%) (p < 0.0001) (Fig. 1d). Results of ROC curve and AUC analysis indicated that both CpG sites are promising biomarker candidates because corresponding AUC were ≥ 0.85 (Fig. 1e and f), showing that selected markers could potentially have clinical utility.

Discussion
Results of our study demonstrated a difference in methylation of CpG islands in MyD88 and ASC/PYCARD/ TMS1 promoter regions in primary tumors of HNSCC and LuSCC. As already mentioned, the distinction between metastatic HNSCC from the primary second primary LuSCC is difficult but crucial for prognosis and treatment options. The second primary lung carcinoma may be low stage and resectable, whereas a metastasis of an HNSCC is a clear sign of tumor dissemination and disease progression, typically without options for curative intervention. A histopathologic distinction is not reliable, and in most cases, not possible. Therefore, development of the novel diagnostic strategies based on precise molecular genetic markers and their implementation is of great interest. It has been observed that specific epigenetic changes, especially DNA methylation, have potential as diagnostic biomarkers. To the best of our knowledge, there is only one study analysing DNA methylation profiling of primary HNSCC and LuSCC which results were further used for different machine learning methods to distinguish metastatic HNSCC from second primary LuSCC [7]. They have demonstrated that DNA methylation profiling is superior in differentiating lung metasta-ses of HNSCC from primary lung cancers arising in patients with HNSCC and, in conjunction with machine learning methods, can solve this specific diagnostic problem.

Our study has several limitations. First of all the study cohort is rather small, therefore we regard our study as a pilot study, whose results need to be reconfirmed by independent studies in different cohorts. Second, due to the small cohort size, clinical/pathological characteristics of patients included are unbalanced, which might also influence our results. Here, we need to stress that we have performed a comparison of obtained methylation data in early-stage HNSCC with early-stage LuSCC (data not presented), and the results were the same as presented for the whole cohort. The third, and probably the most important limitation, is that we did not compare lung metastases of HNSCC with primary LuSCC and primary HNSCC. To further define tested loci as potential diagnostic markers, this is necessary.

In conclusion, the methylation status of selected genes indicated that it is different in primary tumor tissues of different origins. Further analyses, on a larger number of
**Fig. 1** (See legend on next page.)
the samples including metastasis, are needed to confirm its utility for a distinction between second primary LuSCC and metastatic HNSCC in the lung. Results of this pilot study must be considered as preliminary and additional independent studies are necessary to confirm the diagnostic utility of the tested loci/approach.

**Abbreviations**

HNSCC: Head and neck squamous cell carcinoma; LuSCC: Lung squamous cell carcinoma; MyD88: Myeloid differentiation primary response protein 88; ASC/TMS1/PYCARD: Apoptosis-associated speck-like protein containing a caspase recruitment domain; NSCLC: Non-small cell lung cancer; ROC: Receiver operating characteristic; AUC: Area under curve.

**Acknowledgments**

Not applicable.

**Authors' contributions**

JK, together with UZ, designed the study, participated in the data analysis, and wrote the draft of the manuscript; MS, JB, and LKB performed analysis, analyzed the data, contributed to the data acquisition; AJ, LB, and SS performed the pathological analysis and diagnosis; MB, MJ, and MS collected all clinical materials and data. All authors edited the final manuscript, read and approved the final version of the manuscript.

**Funding**

This work was supported by a grant from the Croatian Scientific Foundation (HrZZ-IP-2016-06-1441) to JK.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study was conducted in accordance with the Declaration of Helsinki. All patients signed informed consent and the study was approved by the local ethics committee (University Hospital Center Zagreb).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Division of Molecular Medicine, Laboratory for Advanced Genomics, Ruder Bokčko Institute, Zagreb, Croatia. 2. Department of Otorhinolaryngology, Head and Neck Surgery, Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia. 3. Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia. 4. Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria. 5. Department for Respiratory Diseases, Clinic for Respiratory Diseases Jordanovac, University of Zagreb, School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia. 6. Institute for Human Genetics, Johannes Gutenberg-University Mainz, Mainz, Germany. 7. Faculty for Dental Medicine and Health, University of Osijek, Osijek, Croatia.

**References**

1. Daher T, Tur MK, Brobeil A, Etschmann B, Witte B, Engenhart-Cabillic R, et al. Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Head Neck. 2018:1109–19. https://doi.org/10.1002/hed.25041.

2. Geurts TW, Nederlof PM, Van Brekel MWM, Van Veer LJ, De Jong D, Hart AAM, et al. Cancer therapy: clinical pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? 2005:11:6608–15. https://doi.org/10.1158/1078-0432.CCR-05-0257.

3. Jayaprakash V, Cheng C, Reid M, Dexter EU, Nwogu CE, Hicks W, et al. Prevalent head and neck cancers portend poor prognoses in lung cancer patients. Ann Thorac Surg. 2011;92:1056–61. https://doi.org/10.1016/j.athoracsur.2011.03.146.

4. Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee D, et al. Accelerated discovery distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1998:90:1972–7.

5. Šutić M, Motzek A, Bubanović G, Linke M, Sabol I, Vugrek O, et al. Promoter methylation status of ASC / TMS1 / PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer ( NSCLC ). Transl Lung Cancer Res. 2019;8:1000–15. https://doi.org/10.21037/tlcr.2019.12.08.

6. Kottaridi C, Koureas N, Margari N, Terzakis E, Bilirakis E, Pappas A, et al. A pyrosequencing assay for the quantitative methylation analysis of GAL1 in endometrial Samples: preliminary results. Biomed Res Int. 2015:2015. https://doi.org/10.1155/2015/756359.

7. Jermie R, Bockmayr M, Seegerer P, Bockmayr T, Treue D, Montavon G, et al. Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases. Sci Transl Med. 2019;11 eaaw8513. https://doi.org/10.1126/scitranslmed.aaw8513.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Follow us on Twitter.com/bmc Journals